SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2017 / Cilt: 47 - Sayı: 4

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Aydın YAVUZ
Kürşat DİKMEN
Hasan BOSTANCI
Murat AKIN
Harun KARABACAK
Latife Arzu ARAL
Pages
1263–1266
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: A number of tumor markers detected in the serum or pathological specimens using immunohistochemical methods are used for early detection of malignancies and postoperative follow-up.
📊
Key Findings & Data:Materials and methods: Fifty patients with thyroid cancer and 45 healthy volunteers were included in this study.
💡
Conclusion & Impact:Conclusion: In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: A number of tumor markers detected in the serum or pathological specimens using immunohistochemical methods are used for early detection of malignancies and postoperative follow-up. Human leukocyte antigen-G (HLA-G) is a nonclassic HLA class I molecule. Recent studies suggested a relationship between HLA-G positivity and the stage or the phenotype of the malignancy. In this study, the relationship between serum HLA-G positivity and thyroid cancer was investigated. Materials and methods: Fifty patients with thyroid cancer and 45 healthy volunteers were included in this study. Serum HLA-G levels were measured using ELISA. Results: HLA-G was positive in only 3 out of 50 patients with thyroid cancer (2 papillary, 1 follicular type). On the other hand, HLA-G was positive in 20 out of 45 healthy subjects (P < 0.001). The prevalence of detectable levels of serum HLA-G was independent of sex and age in the whole study population. No correlation was found between serum HLA-G value and thyroid hormone profile, neither in papillary thyroid cancer nor follicular thyroid cancer patients. Conclusion: In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.

🔖

Cite This Article

YAVUZ, A., DİKMEN, K., BOSTANCI, H., AKIN, M., KARABACAK, H., ARAL, L. A. (2022). Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer. Turkish Journal of Medical Sciences, Cilt: 47 - Sayı: 4, 1263–1266. https://ajindex.com/articles/610952

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Gocun PU, Karakus E, Bulutay P, Akturk M, Akin M, Poyraz A. What is the malignancy risk for atypia of undetermined significance? Three years’ experience at a university hospital in Turkey. Cancer Cytopathol 2014; 122: 604-610
  2. Urasevic M, Dummer R. HLA-G and IL-10 expression in human cancer--different stories with the same message. Semin Cancer Biol 2003; 13: 337-342. 3. de Figueiredo Feitosa NL, Crispim JC, Zanetti BR, Magalhães PK, Soares CP, SoaresEG, Neder L, Donadi EA, Maciel LM. HLA-G is differentially expressed in thyroid tissues. Thyroid 2014; 24: 585-592
  3. Nunes LM, Ayres FM, Francescantonio IC, Saddi VA, Avelino MA, Alencar Rde C, Silva RC, Meneghini AJ, Wastowski IJ. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol 2013; 74: 447-451
  4. Bainbridge D, Ellis S, Le Bouteiller P, Sargent I. HLA-G remains a mystery. Trends Immunol 2001; 22: 548-552
  5. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33: 125- 134
  6. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N. HLA-G mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11: 1351-1356
  7. Ellis SA, Sargent IL, Redman CW, McMichael AJ. Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line. Immunology 1986; 59: 595- 601
  8. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmuller H, Hohlfeld R, Melms A, Weller M. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 2003; 126: 176-185
  9. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with highgrade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159: 817-824
  10. Baştürk B, Karakayalı F, Emiroğlu R, Sözer O, Haberal A, Bal D, Haberal M. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc 2006; 38: 571-574
  11. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B. Expression of H